Jan 14 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including BlackRock, Cencora and UnitedHealth on Tuesday.
HIGHLIGHTS
* BlackRock BLK.N: JP Morgan raises target price to $971 from $914 |
* Cencora COR.N: Baird raises target price to $305 from $302 |
* GE Vernova Inc GEV.N: JP Morgan raises target price to $374 from $367 |
* UnitedHealth UNH.N: Leerink Partners raises target price to $675 from $600 |
* Walker & Dunlop Inc WD.N: Jefferies cuts target price to $115 from $135 |
Following is a summary of research actions on U.S. companies reported by Reuters on Tuesday. Stock entries are in alphabetical order.
* American Eagle Outfitters Inc AEO.N: Jefferies cuts target price to $17 from $19 |
* Apollo Commercial Real Estate Finance Inc ARI.N: KBW cuts target to $8.75 from $9 |
* Appian Corp APPN.O: Keybanc assumes coverage with sector weight rating |
* Arbor Realty Trust Inc ABR.N: KBW cuts target price to $13.5 from $14.25 |
* Ares Commercial Real Estate Corp ACRE.N: KBW cuts target price to $6 from $7 |
* BlackRock BLK.N: JP Morgan raises target price to $971 from $914 |
* Blackstone Mortgage Trust Inc BXMT.N: KBW cuts target price to $18.5 from $19 |
* Calumet Inc CLMT.O: H.C. Wainwright raises target price to $33 from $25 |
* Cencora COR.N: Baird raises target price to $305 from $302 |
* Claros Mortgage Trust Inc CMTG.N: KBW cuts target price to $4 from $6.5 |
* Evolent Health Inc EVH.N: RBC cuts target price to $17 from $20 |
* First Citizens Bancshares FCNCA.O: KBW raises to outperform from market perform |
* Fox Corp FOXA.O: JP Morgan raises target price to $49 from $42 |
* GE Vernova Inc GEV.N: JP Morgan raises target price to $374 from $367 |
* Granite Point Mortgage Trust Inc GPMT.N: KBW cuts target price to $2.85 from $3.25 |
* Guild Holdings Co GHLD.N: Jefferies cuts target price to $16 from $18 |
* Intra-Cellular Therapies ITCI.O: Leerink Partners cuts to market perform from outperform |
* Intra-Cellular Therapies Inc ITCI.O: Leerink Partners raises target to $132 from $100 |
* Intra-Cellular Therapies Inc ITCI.O: Piper Sandler cuts to neutral from overweight |
* Intra-Cellular Therapies Inc ITCI.O: Piper Sandler raises target to $132 from $107 |
* IRhythm Technologies Inc IRTC.O: Needham raises target price to $112 from $96 |
* KKR Real Estate Finance Trust Inc KREF.N: KBW cuts target price to $12.25 from $13 |
* Ladder Capital Corp LADR.N: KBW cuts target price to $12.75 from $13 |
* LGI Homes Inc LGIH.O: JP Morgan cuts target price to $80 from $82 |
* Mercury General Corp MCY.N: Raymond James cuts target price to $70 from $80 |
* Moderna MRNA.O: Leerink Partners cuts target price to $27 from $31 |
* Nexpoint Real Estate Finance Inc NREF.N: KBW cuts target price to $15.5 from $16.5 |
* Pegasystems Inc PEGA.O: Keybanc assumes coverage with overweight rating; target $118 |
* Pennymac Financial Services Inc PFSI.N: Jefferies cuts target price to $120 from $130 |
* Ready Capital Corp RC.N: KBW cuts target price to $6.25 from $6.75 |
* Rocket Companies Inc RKT.N: Jefferies cuts target price to $11.5 from $15 |
* Starwood Property Trust Inc STWD.N: KBW cuts target price to $22 from $22.5 |
* T Rowe price Group Inc TROW.O: KBW cuts target price to $111 from $116 |
* UnitedHealth UNH.N: Leerink Partners raises target price to $675 from $600 |
* UWM Holdings Corp UWMC.N: Jefferies cuts target price to $8 from $9 |
* Walgreens WBA.O: HSBC raises target price to $10 from $7.6 |
* Walker & Dunlop Inc WD.N: Jefferies cuts target price to $115 from $135 |
* Warner Bros Discovery Inc WBD.O: JP Morgan raises target price to $10 from $9 |
(Compiled by Bengaluru Newsroom)
((Diaries@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.